Actively Recruiting
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-02-20
644
Participants Needed
3
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative research is captured by its acronym, DISRUPT: Diversity \& IncluSion in Research Underpinning Prevention \& Therapy Trials. To disrupt the norms that maintain heightened risk and poorer outcomes experienced by BIPOC, the research team propose three integrated and synergistic aims to improve diversity and inclusion in CTs through disruptive approaches at the community (Aim 1), provider, system and patient (Aim 2), and basic and translational scientist levels (Aim 3). All three aims focus on metrics for changing norms reified in institutional policies and established practice that will provide essential evidence to translate and scale these changes to institutions and networks involved in cancer treatment research. In Aim 1, the research team will partner with local organizations to formulate and disseminate new norms regarding cancer care and research and diffuse these new norms throughout the community via community organizations and Health Ambassadors bringing a different vantage point on CTs, raising awareness and increasing demand for access to cancer research. In Aim 2, the research team will create an electronic approach to identify key clinical characteristics of patients and trials and match patients and trials and bring these data to patients and their physicians at the time of key decisions. In Aim 3, the research team will provide and integrate essential experiential training in diversity, social determinants of health and the importance of conducting community-relevant work into basic and translational science training. This DISRUPT proposal provides the foundation to disrupt norms about cancer clinical trials in our communities, delivery systems and scientific research enterprises.
CONDITIONS
Official Title
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 21 years or older with invasive breast, lung, or liver cancer who face a treatment decision
- Patients of doctors who have agreed to participate in the study
- Able to give consent and speak either English or Spanish
- Oncologists and advanced practitioners caring for patients with breast, lung, or liver cancer, including medical and surgical oncologists, interventional radiologists, and hepatologists are eligible for provider recruitment
You will not qualify if you...
- Patients unable to give consent
- Patients unable to understand English or Spanish
- Patients without invasive breast or liver cancer
- Patients not facing an imminent treatment decision
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
2
Herbert Irving Comprehensive Cancer Care Center
New York, New York, United States, 10032
Actively Recruiting
3
Albert Einstein College of Medicine
The Bronx, New York, United States, 10461
Actively Recruiting
Research Team
R
Radhi Yagnik
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here